Lancet Diabetes and Endocrinology

Journal

Publication Venue For

  • Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.  7:899-911. 2019
  • Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.  7:618-628. 2019
  • Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials.  6:879-890. 2018
  • Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.  6:445-454. 2018
  • Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.  4:840-849. 2016
  • Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data.  3:514-525. 2015
  • Diabetic kidneys do deserve a lifestyle change.  2:776. 2014
  • Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of the Look AHEAD randomised clinical trial.  2:801-809. 2014
  • Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study.  2:289-297. 2014
  • The Look AHEAD study: A missed opportunity - Authors' Reply.  2:776. 2014
  • International Standard Serial Number (issn)

  • 2213-8587
  • Electronic International Standard Serial Number (eissn)

  • 2213-8595